Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2021—PerkinElmer announced that its PerkinElmer New Coronavirus Nucleic Acid Detection Kit received emergency use authorization from the FDA to test individuals without symptoms or other reasons to suspect COVID-19 infection.
March 2021—Quidel received emergency use authorization from the FDA to market its Solana SARS-CoV-2 assay, an isothermal reverse transcriptase–helicase dependent amplification (RT-HDA) assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal and nasal swab specimens in viral transport media from patients suspected of having COVID-19 by their health care provider.
March 2021—LGC announced its acquisition of Technopath Clinical Diagnostics, expanding LGC’s position in the clinical diagnostics QC market. Technopath’s chemistry and immunoassay controls will be brought into LGC’s clinical diagnostics business unit.
March 2021—Visby Medical announced FDA authorization of the company’s rapid PCR COVID-19 test for use at the point of care by organizations with a CLIA certificate of waiver.
March 2021—Siemens Healthineers announced the company’s laboratory-based SARS-CoV-2 Antigen Assay obtained the CE mark. The test runs on the Atellica IM analyzer, which has the capacity to run 440 tests per hour, and the Advia Centaur XP and XPT immunoassay systems.
March 2021—Sarstedt introduced the Microvette APT for capillary blood collection. The tubes are available with either a 250-µL or 500-µL maximum fill volume. Both options have 75 × 13 mm external tube dimensions with a false bottom, feature a thin collection rim, are prepared with K2 EDTA, and have a pierceable and leak-resistant cap. The Microvette APT 250 offers a preassembled end-to-end capillary for collection. The Microvette APT 500 has a variable filling volume from 250 to 500 µL.
March 2021—Thermo Fisher Scientific announced the availability of a direct from saliva PCR test for COVID-19 to enable widespread, high-frequency surveillance testing. The Applied Biosystems TaqCheck SARS-CoV-2 Fast PCR Assay Kit is a multiplexed RT-PCR assay for the qualitative detection and characterization of SARS-CoV-2 RNA (S and N genes) plus a human RNAse P assay to help assess sample adequacy. The assays are designed to work with raw saliva from research samples.
March 2021—Seegene announced it has developed the first COVID-19 diagnostic variant test capable of screening COVID-19 and identifying multiple mutant variations in a single reaction.
March 2021—A rapid coronavirus test that provides results for COVID-19 in 39 minutes is available on the Vivalytic, a point-of-care platform by Randox Laboratories and Bosch. The CE-approved test has a sensitivity of 98 percent and a specificity of 100 percent.
March 2021—PerkinElmer launched its PerkinElmer COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens. The lateral flow immunoassay test can be used to screen or to aid in diagnoses of COVID-19 in asymptomatic or symptomatic individuals. A positive or negative result can be obtained in 15 minutes.
